EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 552 (2024) E3S Web Conf., 552 (2024) 01069 References
Open Access
Issue
E3S Web Conf.
Volume 552, 2024
16th International Conference on Materials Processing and Characterization (ICMPC 2024)
Article Number 01069
Number of page(s) 20
DOI https://doi.org/10.1051/e3sconf/202455201069
Published online 23 July 2024
  1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. [CrossRef] [PubMed] [Google Scholar]
  2. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355. [CrossRef] [PubMed] [Google Scholar]
  3. Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., & & Loi, S. (2020). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine, 382(21), 2108–2121. [Google Scholar]
  4. Motzer, R. J., Tannir, N. M., McDermott, D. F., Frontera, O. A., Melichar, B., Choueiri, T. K., & & McHenry, M.B. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine, 378(14), 1277–1290. [CrossRef] [PubMed] [Google Scholar]
  5. Burki, T. K. (2018). Encouraging results from CAR T-cell therapy in glioblastoma. The Lancet Oncology, 19(11), e570. [Google Scholar]
  6. Maio, M., Grob, J. J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., & & Chin, K. (2015). Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of Clinical Oncology, 33(10), 1191–1196. [CrossRef] [PubMed] [Google Scholar]
  7. FDA Approves First CAR-T Cell Therapy for Multiple Myeloma. (2021). U.S. Food and Drug Administration. [Press Release] [Google Scholar]
  8. Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., & & Hart, L. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England Journal of Medicine, 372(8), 724–734. [CrossRef] [PubMed] [Google Scholar]
  9. Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., & & Sargent, D. (2017). iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology, 18(3), e143–e152. [CrossRef] [PubMed] [Google Scholar]
  10. Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., & & Eisenberger, M.A. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502–1512. [CrossRef] [PubMed] [Google Scholar]
  11. Chabner, B. A., & Roberts, T. G. (2005). Chemotherapy and the war on cancer. Nature Reviews Cancer, 5(1), 65–72. [CrossRef] [PubMed] [Google Scholar]
  12. Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205(2), 275–292. [CrossRef] [PubMed] [Google Scholar]
  13. Yap, T. A., & Workman, P. (2012). Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annual Review of Pharmacology and Toxicology, 52, 549–573. [CrossRef] [PubMed] [Google Scholar]
  14. Gerber, D. E., & Schiller, J. H. (2013). Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. Journal of Clinical Oncology, 31(8), 1009–1020. [CrossRef] [PubMed] [Google Scholar]
  15. Jordan, V. C. (2003). Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell, 3(3), 207–212. [CrossRef] [PubMed] [Google Scholar]
  16. Loibl, S., Gianni, L., HER2-positive breast cancer. (2017). The Lancet, 389(10087), 2415–2429. [CrossRef] [Google Scholar]
  17. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. [CrossRef] [PubMed] [Google Scholar]
  18. Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer, 2(1), 48–58. [CrossRef] [PubMed] [Google Scholar]
  19. Tortora, G. J., & Dusheck, J. (2017). Principles of anatomy and physiology. Wiley. [Google Scholar]
  20. Fojo, T., & Bates, S. (2003). Strategies for reversing drug resistance. The Oncologist, 8(6), 467–473. [Google Scholar]
  21. Rodriguez-Barrueco, R., Yu, J., & Saif, M. W. (2016). New insights into the mechanisms of action of trabectedin in myxoid liposarcoma. Oncology Reviews, 10(2), 314. [Google Scholar]
  22. Den Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., & & Pieters, R. (2009). A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. The Lancet Oncology, 10(2), 125–134. [CrossRef] [PubMed] [Google Scholar]
  23. Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330–338. [CrossRef] [PubMed] [Google Scholar]
  24. Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., & Ryoo, B. Y. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine, 379(1), 54–63. [CrossRef] [PubMed] [Google Scholar]
  25. Yap, T. A., & Workman, P. (2012). Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annual Review of Pharmacology and Toxicology, 52, 549–573. [CrossRef] [PubMed] [Google Scholar]
  26. Ali, S. M., Yao, M., Yao, J., Wang, J., Cheng, Y., Schrock, A. B., & & Sehn, L.H. (2019). Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. The Oncologist, 24(12), 1532–1539. [Google Scholar]
  27. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. [CrossRef] [PubMed] [Google Scholar]
  28. Green_Chemistry_and_Synthesis_of_Anticancer_Molecule (2018), Areej Mohammad Altaweel, Shagufta Perveen [Google Scholar]
  29. Bioorg Med Chem Lett 2010 Apr 1;20(7):2306–10. doi: 10.1016/j.bmcl.2010.01.147. Epub 2010 Feb 2. [CrossRef] [PubMed] [Google Scholar]
  30. Bin Zhao, Yingshuai Wang, Xianxian Yao, Danyang Chen, Mingjian Fan, Zhaokui Jin & Qianjun He Nature Communications volume 12, Article number: 1345 (2021) [CrossRef] [PubMed] [Google Scholar]
  31. Rodriguez-Barrueco, R., Yu, J., & Saif, M. W. (2016). New insights into the mechanisms of action of trabectedin in myxoid liposarcoma. Oncology Reviews, 10(2), 314. [Google Scholar]
  32. Den Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., & & Pieters, R. (2009). A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. The Lancet Oncology, 10(2), 125–134. [CrossRef] [PubMed] [Google Scholar]
  33. Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330–338. [CrossRef] [PubMed] [Google Scholar]
  34. Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., & Ryoo, B. Y. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine, 379(1), 54–63. [CrossRef] [PubMed] [Google Scholar]
  35. Yap, T. A., & Workman, P. (2012). Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annual Review of Pharmacology and Toxicology, 52, 549–573. [CrossRef] [PubMed] [Google Scholar]
  36. Ali, S. M., Yao, M., Yao, J., Wang, J., Cheng, Y., Schrock, A. B., & & Sehn, L.H. (2019). Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. The Oncologist, 24(12), 1532–1539. [Google Scholar]
  37. Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature, 541(7637), 321–330. [CrossRef] [PubMed] [Google Scholar]
  38. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252–264. [CrossRef] [PubMed] [Google Scholar]
  39. Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., & & Geyer C.E.Jr, (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. New England Journal of Medicine, 379(2), 111–121. [CrossRef] [PubMed] [Google Scholar]
  40. Motzer, R. J., Tannir, N. M., McDermott, D. F., Frontera, O. A., Melichar, B., Choueiri, T. K., & & McHenry, M.B. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine, 378(14), 1277–1290. [CrossRef] [PubMed] [Google Scholar]
  41. Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017). Tumor mutational burden and response rate to PD-1 inhibition. New England Journal of Medicine, 377(25), 2500–2501. [CrossRef] [PubMed] [Google Scholar]
  42. FDA Approves First CAR-T Cell Therapy for Multiple Myeloma. (2021). U.S. Food and Drug Administration. [Google Scholar]
  43. Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1), 1–10. [CrossRef] [PubMed] [Google Scholar]
  44. Bezu, L., Gomes-de-Silva, L.C., Dewitte, H., Breckpot, K., & Fucikova, J. (2019). Combinatorial strategies for the induction of immunogenic cell death. Frontiers in Immunology, 10, 1–16. [CrossRef] [PubMed] [Google Scholar]
  45. Sheng, J. Y., Sharma, D., Jerome, H., Lei, X., & Rizzo, K. A. (2020). Recent advances in oral chemotherapy: implications for cancer treatment and oral health. The Journal of the American Dental Association, 151(8), 572–579. [Google Scholar]
  46. Riaz, N., Havel, J. J., & Makarov, V. (2017). Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell, 171(4), 934–94 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.